| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e5edd48190cba3fa70dd3975efd9831 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-325
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-224 |
| filingDate |
1978-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b08157b5b90b7604cb58ebb9eb0ef83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5647df608c4f41f5cdb09f1ecf6cc66d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11e74fbe5860df544b05b8cbff9c7b23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a4a7bdf6107f676c833f83e6335742f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dbacd7dfe98da8e87f75fcfbd081425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d91487c87c26647f2f5d75cd14f0dccc |
| publicationDate |
1979-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0002680-A2 |
| titleOfInvention |
4-Spectinomycylamin and its physiologically acceptable salts, method of preparation and pharmaceutical products containing these substances |
| abstract |
The invention relates to the 4-spectinomycylamine of the formula as a new substance its physiologically compatible acid addition salts with inorganic or organic acids and their preparation by methods known per se.n n n The spectinomycin of formula I and its acid addition salts act against a large number of gram-positive and gram-negative bacteria and are characterized by a wide therapeutic range, they are particularly suitable for the prophylaxis and chemotherapy of local and systemic infections in human and veterinary medicine. Specinomycin can be produced, for example, by reducing a spectinomycin oxime, optionally provided with protective groups, the protective group being subsequently split off again. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9886807-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4913085-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2532950-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017140597-A1 |
| priorityDate |
1977-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |